Sunshield Chemicals Q2 FY26: ₹122 Crore Revenue, ₹7.23 Crore Profit, and a ₹901 Rights Issue — The Little Specialty Chemist That Could (and Did)
1. At a Glance
Meet Sunshield Chemicals Ltd, the smallcap chemical maverick from Raigad, Maharashtra, that just told the market, “I might be small, but I compound faster than your mutual fund.” With a market cap of ₹849 crore, a P/E of 39.6x, and a stock price of ₹965, this 1986-born underdog has pulled off a sharp Q2 FY26 — Revenue ₹122 crore (+31.7% YoY), PAT ₹7.23 crore (+127% YoY), and EPS ₹8.22.
Operating margins held steady at 11.45%, ROE at 16.4%, and debt manageable at ₹87.6 crore (0.81x D/E). The company’s antioxidant and THEIC product lines are on fire (figuratively), catering to Lubrizol, Asian Paints, Solvay, and Godrej.
But here’s the real masala: In October 2025, Sunshield closed a ₹129.9 crore rights issue at ₹901/share — oversubscribed and hotter than a Navratri IPO. The funds? For expansion, modernization, and perhaps to flex at the next specialty chemical conference.
From being a sleepy “niche chemicals” player to a fast-scaling, margin-expanding exporter with a growing domestic moat — Sunshield just proved that even smallcaps can shine brighter than the fluoropolymers in Navin Fluorine’s labs.
2. Introduction
If Sunshield Chemicals were a Bollywood character, it’d be the nerdy scientist in 3 Idiots — quiet, underappreciated, but secretly inventing something explosive. Incorporated in 1986 and largely ignored for decades, the company now finds itself in the elite club of “specialty chemical multibaggers” that quietly multiply while everyone else obsesses over largecaps.
Over the last five years, revenue has grown from ₹190 crore to ₹431 crore — a 2.3x rise. PAT, though fluctuating, has matured with age — now sitting at ₹21.4 crore TTM with a 16.9% growth rate. The market, of course, noticed — the stock has rallied 52% in five years, with a minor breather this year (-1.5%).
But Sunshield isn’t just making chemicals; it’s making chemistry happen. Its client list reads like the “Forbes list of chemical royalty” — Lubrizol, Solvay, Asian Paints, Elantas Europe, Godrej, and Indian Additives. From antioxidants to chain extenders, its portfolio touches everything — plastics, lubricants, paints, agro, and cosmetics.
The FY26 rights issue has given it the firepower to expand the antioxidant plant, modernize the ethoxylate line, and push capacity from 16,256 MTPA to 18,076 MTPA. In a world chasing China+1, Sunshield is silently positioning itself as “India + smart execution.”
3. Business Model – WTF Do They Even Do?
Sunshield Chemicals manufactures specialty chemicals, which is corporate-speak for “we make complex molecules for products you use daily but can’t pronounce.”
Their key product lines:
THEIC (Tris Hydroxy Ethyl Isocyanurate): Used in PVC stabilizers and heat stabilizers. Basically, the reason your plastic doesn’t melt like ice cream in Nagpur.
Ethoxylates & Propoxylates: Used across paper, agro, dyes, and detergents — think emulsifiers, dispersants, solubilizers.
Antioxidants: The unsung heroes in lubricants, rubbers, and plastics — preventing degradation and adding life.
HQEE (Hydroquinone Bis(2-hydroxyethyl)ether): A crosslinking agent in polyurethanes, a fancy way to say “makes stuff tougher.”
BC 700: Paint and varnish industry’s matte magician.
The company supplies to 80+ industries across home care, paints, coatings, agro, and polymers. Its domestic dominance (83% of sales in FY25) reflects its shift from export dependency (35% in FY23 → 17% in FY25). The focus is now on high-margin Indian customers like Asian Paints and Godrej Industries, who prefer local innovation over imported headache.
Essentially, Sunshield’s business model = custom chemistry meets recurring contracts, all brewed in Raigad.
Commentary: That’s a YoY profit explosion — over 2x jump in bottom line. OPM remains stable, proving the company’s expansion didn’t mess up efficiency. If FY25 was the “cleanup” phase, FY26 is the “compounding” one. The quarterly EPS rise shows genuine business momentum — not one-time accounting magic.
5. Valuation Discussion – Fair Value Range
Let’s play valuation chemistry:
(A) P/E Approach
Annualised EPS: ₹32.9
Industry P/E: 32x → Fair range = ₹900 – ₹1,050
(B) EV/EBITDA Approach
EV = ₹936 crore
EBITDA (TTM) = ₹45 crore
EV/EBITDA = 20.8x vs peer avg 25x → Fair range = ₹950 – ₹1,150
(C) DCF (Educational) Assume 12% CAGR earnings for 5 years, terminal growth 4%, CoE 11% → ₹920 – ₹1,180 range
✅ Educational Fair Value Range: ₹900 – ₹1,150 per share This range is for educational purposes only and not investment advice.
6. What’s Cooking – News, Triggers, Drama
Grab your popcorn:
Rights Issue (₹129.9 Cr @ ₹901/share): Successfully closed in October 2025. The funds will modernize plants, reduce debt, and fuel the next capacity ramp-up. Imagine giving steroids to a lab flask.
Capacity Expansion: Antioxidant and EO/Theic unit expansion completed in May 2025 — this should start reflecting in FY26 revenue.
CRISIL Upgrade (Apr 2024): Improved credit rating post consistent profitability and deleveraging.
Penalty Drama (FY24): A ₹4.9 crore fine for an undisclosed compliance issue — minor but enough for the gossip column.
Promoter Flex: Holding increased to 66% in FY26 — a confidence signal when most smallcap owners are busy pledging shares to buy Teslas.
If the company sustains 30% topline growth with steady margins, it’s only a matter of time before it’s invited to the “Vinati Organics–Deepak Nitrite” WhatsApp group.
7. Balance Sheet
(₹ Cr)
Mar FY23
Mar FY24
Sep FY25
Total Assets
177
229
279
Net Worth
66
82
107
Borrowings
77
85
88
Other Liabilities
34
61
84
Total Liabilities
177
229
279
Quick takes:
Net worth grew 60% in two years — thanks to retained profits and the upcoming rights infusion.
Debt remains flat, meaning expansion is funded smartly.
Balance sheet = small but clean. Like a bachelor’s kitchen before Diwali.
